| scholarly article | Q13442814 |
| P5530 | Altmetric DOI | 10.1007/S13311-017-0575-2 |
| P6179 | Dimensions Publication ID | 1091923443 |
| P356 | DOI | 10.1007/S13311-017-0575-2 |
| P8608 | Fatcat ID | release_dxmf6jvq5bf2jb6kslu6joycoi |
| P953 | full work available at URL | https://www.proquest.com/openview/362d72ceea05736deb5f30a729e93089 |
| P4028 | Google Scholar paper ID | 14425841214454601321 |
| P7100 | Lens ID | 011-683-227-866-568 |
| P7916 | Mendeley publication ID | 1e354408-f475-371d-b858-6e7d0228a8b6 |
| P6366 | Microsoft Academic ID | 2759315373 |
| P243 | OCLC control number | 7250344724 |
| P10283 | OpenAlex ID | W2759315373 |
| P932 | PMC publication ID | 5722777 |
| P698 | PubMed publication ID | 28952036 |
| P5875 | ResearchGate publication ID | 320050701 |
| P7710 | ScienceOpen publication ID | 676e6d5b-3747-4535-974e-14a14871e372 |
| P8299 | Semantic Scholar corpus ID | 23878046 |
| P4011 | Semantic Scholar paper ID | c16a579b8139b4ed839e35565fb99f3b9ae12e14 |
| P8372 | Web of Science work ID | 000417695200019 |
| P50 | author | Rachel P. M. Abrams | Q102335686 |
| P2093 | author name string | Avindra Nath | |
| Jamie Solis | |||
| P2860 | cites work | TIM-family proteins promote infection of multiple enveloped viruses through virion-associated phosphatidylserine | Q21131381 |
| Zika virus. I. Isolations and serological specificity | Q22240545 | ||
| Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007 | Q22241244 | ||
| Zika virus: a previously slow pandemic spreads rapidly through the Americas | Q22242663 | ||
| Zika Virus in the Americas — Yet Another Arbovirus Threat | Q22248116 | ||
| Zika Virus Outbreak on Yap Island, Federated States of Micronesia | Q22250881 | ||
| A small-molecule dengue virus entry inhibitor | Q22309806 | ||
| Zika virus in Brazil and macular atrophy in a child with microcephaly | Q22330676 | ||
| Detection of Zika virus in saliva | Q22330713 | ||
| Zika virus infections imported to Italy: clinical, immunological and virological findings, and public health implications | Q22330725 | ||
| Detection of Zika virus in urine | Q22330729 | ||
| Evidence of perinatal transmission of Zika virus, French Polynesia, December 2013 and February 2014 | Q22330746 | ||
| Potential for Zika virus transmission through blood transfusion demonstrated during an outbreak in French Polynesia, November 2013 to February 2014 | Q22330747 | ||
| Full-length sequencing and genomic characterization of Bagaza, Kedougou, and Zika viruses | Q22330782 | ||
| Zika virus, a cause of fever in Central Java, Indonesia | Q22330869 | ||
| Isolation of Zika Virus from Aedes Aegypti Mosquitoes in Malaysia * | Q22330876 | ||
| Zika virus: a report on three cases of human infection during an epidemic of jaundice in Nigeria | Q22330904 | ||
| Zika Virus Associated with Microcephaly | Q22683189 | ||
| Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study | Q23012849 | ||
| Drug repositioning: identifying and developing new uses for existing drugs | Q29614779 | ||
| Composition and three-dimensional architecture of the dengue virus replication and assembly sites | Q29615112 | ||
| Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options | Q29620126 | ||
| Sofosbuvir for previously untreated chronic hepatitis C infection | Q29620137 | ||
| Zika virus: high infectious viral load in semen, a new sexually transmitted pathogen? | Q30051605 | ||
| A conformational switch high-throughput screening assay and allosteric inhibition of the flavivirus NS2B-NS3 protease | Q30145558 | ||
| Pediatric Drug Nitazoxanide: A Potential Choice for Control of Zika | Q30145642 | ||
| Characterization of the Zika virus two-component NS2B-NS3 protease and structure-assisted identification of allosteric small-molecule antagonists | Q30145664 | ||
| Polysulfonate suramin inhibits Zika virus infection | Q30145667 | ||
| Prospects for a Zika Virus Vaccine | Q30235612 | ||
| In silico screening of small molecule libraries using the dengue virus envelope E protein has identified compounds with antiviral activity against multiple flaviviruses. | Q30381077 | ||
| Efficacy of the broad-spectrum antiviral compound BCX4430 against Zika virus in cell culture and in a mouse model | Q30395163 | ||
| The endoplasmic reticulum provides the membrane platform for biogenesis of the flavivirus replication complex | Q30484619 | ||
| Pathogenic flaviviruses. | Q31146025 | ||
| Unwinding the 'Gordian knot' of helicase action. | Q31879197 | ||
| Pregnancy outcome following gestational exposure to azithromycin | Q33245155 | ||
| FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension | Q33365592 | ||
| Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer | Q33423263 | ||
| Proteasome inhibitors: a novel class of potent and effective antitumor agents. | Q33864458 | ||
| Bromocriptine mesylate: FDA-approved novel treatment for type-2 diabetes | Q33874067 | ||
| Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. | Q34040052 | ||
| Acute myelitis due to Zika virus infection | Q23014548 | ||
| Infectious Zika viral particles in breastmilk | Q23038269 | ||
| The Viral Polymerase Inhibitor 7-Deaza-2'-C-Methyladenosine Is a Potent Inhibitor of In Vitro Zika Virus Replication and Delays Disease Progression in a Robust Mouse Infection Model | Q23309956 | ||
| The 3.8 Å resolution cryo-EM structure of Zika virus | Q23680595 | ||
| Structures of the Zika Virus Envelope Protein and Its Complex with a Flavivirus Broadly Protective Antibody | Q24067948 | ||
| Structure of the thermally stable Zika virus | Q24082710 | ||
| Effect of administration of antihelminthics for soil-transmitted helminths during pregnancy | Q24187087 | ||
| Emergence of Congenital Zika Syndrome: Viewpoint From the Front Lines | Q24261097 | ||
| Nucleoside inhibitors of Zika virus | Q24278770 | ||
| The crystal structure of Zika virus helicase: basis for antiviral drug design | Q24332542 | ||
| Mefloquine safety and tolerability in pregnancy: a systematic literature review | Q24599164 | ||
| 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro | Q24609215 | ||
| The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic | Q24655011 | ||
| Endemic paragonimiasis in Africa | Q24655333 | ||
| Structure of dengue virus: implications for flavivirus organization, maturation, and fusion | Q24736810 | ||
| Pathology of congenital Zika syndrome in Brazil: a case series | Q25139131 | ||
| Crystal structure of Zika virus NS2B-NS3 protease in complex with a boronate inhibitor | Q25707171 | ||
| The clinically approved antiviral drug sofosbuvir impairs Brazilian zika virus replication | Q25707196 | ||
| Structure of the NS3 helicase from Zika virus | Q26247146 | ||
| Suspected Female-to-Male Sexual Transmission of Zika Virus - New York City, 2016 | Q26247236 | ||
| A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection | Q26252076 | ||
| Zika Virus Targets Different Primary Human Placental Cells, Suggesting Two Routes for Vertical Transmission | Q26252081 | ||
| Zika virus in the female genital tract | Q26252503 | ||
| Complete Genome Sequences of Three Historically Important, Spatiotemporally Distinct, and Genetically Divergent Strains of Zika Virus: MR-766, P6-740, and PRVABC-59 | Q26484330 | ||
| Zika Virus Disrupts Phospho-TBK1 Localization and Mitosis in Human Neuroepithelial Stem Cells and Radial Glia | Q26693468 | ||
| Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen | Q26747306 | ||
| Flavivirus cell entry and membrane fusion | Q26852458 | ||
| Flavivirus entry receptors: an update | Q26866329 | ||
| Structural basis of Zika virus helicase in recognizing its substrates | Q26970833 | ||
| Nitazoxanide: a first-in-class broad-spectrum antiviral agent | Q27021914 | ||
| Adenosine Analog NITD008 Is a Potent Inhibitor of Zika Virus | Q27463110 | ||
| Mechanisms of activation and inhibition of Zika virus NS2B-NS3 protease | Q27463132 | ||
| Bithionol blocks pathogenicity of bacterial toxins, ricin, and Zika virus | Q27468627 | ||
| Crystal Structure of West Nile Virus Envelope Glycoprotein Reveals Viral Surface Epitopes | Q27477610 | ||
| A ligand-binding pocket in the dengue virus envelope glycoprotein | Q27477685 | ||
| Proteolytic activation of tick-borne encephalitis virus by furin | Q27480892 | ||
| Insights into RNA unwinding and ATP hydrolysis by the flavivirus NS3 protein | Q27487462 | ||
| Architects of assembly: roles of Flaviviridae non-structural proteins in virion morphogenesis | Q27490193 | ||
| An adenosine nucleoside inhibitor of dengue virus | Q27490481 | ||
| Structure of the immature dengue virus at low pH primes proteolytic maturation | Q27650165 | ||
| The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution | Q27730234 | ||
| Structure of the NS2B-NS3 protease from Zika virus after self-cleavage | Q27869770 | ||
| The FDA-approved drug sofosbuvir inhibits Zika virus infection | Q27924226 | ||
| Adenosine triphosphate analogs can efficiently inhibit the Zika virus RNA-dependent RNA polymerase | Q27924228 | ||
| Antiviral activities of selected antimalarials against dengue virus type 2 and Zika virus | Q27924733 | ||
| Structures of NS5 Methyltransferase from Zika Virus | Q27928070 | ||
| Crystal structure of unlinked NS2B-NS3 protease from Zika virus | Q27980324 | ||
| Evaluation of anti-Zika virus activities of broad-spectrum antivirals and NIH clinical collection compounds using a cell-based, high-throughput screen assay | Q27980548 | ||
| 2,8-bis(trifluoromethyl)quinoline analogs show improved anti-Zika virus activity, compared to mefloquine | Q28114553 | ||
| Structural Insight into NS5 of Zika Virus Leading to the Discovery of MTase Inhibitors | Q28114685 | ||
| The Zika virus methyltransferase: structure and functions for drug design perspectives | Q28114691 | ||
| Extended substrate specificity and first potent irreversible inhibitor/activity-based probe design for Zika virus NS2B-NS3 protease | Q28119320 | ||
| Zika virus cell tropism in the developing human brain and inhibition by azithromycin | Q28119685 | ||
| The risk associated with aprotinin in cardiac surgery | Q28293732 | ||
| Niclosamide is a proton carrier and targets acidic endosomes with broad antiviral effects | Q28484821 | ||
| Sensitivity of mitochondrial transcription and resistance of RNA polymerase II dependent nuclear transcription to antiviral ribonucleosides | Q28485227 | ||
| Inhibition of pyrimidine biosynthesis pathway suppresses viral growth through innate immunity | Q28534057 | ||
| Identification of three antiviral inhibitors against Japanese encephalitis virus from library of pharmacologically active compounds 1280 | Q28536473 | ||
| Proteasome Inhibition Suppresses Dengue Virus Egress in Antibody Dependent Infection | Q28550953 | ||
| Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis | Q28552507 | ||
| Analysis of Ribonucleotide 5’ -Triphosphate Analogs as Potential Inhibitors of Zika Virus RNA-dependent RNA Polymerase Using Non-Radioactive Polymerase Assays | Q28581011 | ||
| Induction of Endogenous Virus and of Thymidine Kinase by Bromodeoxyuridine in Cell Cultures Transformed by Friend Virus | Q34052299 | ||
| The drugs we have and the drugs we need against major helminth infections | Q34125793 | ||
| Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug | Q34246661 | ||
| Emerging principles in protease-based drug discovery | Q34282102 | ||
| Identification and analysis of hepatitis C virus NS3 helicase inhibitors using nucleic acid binding assays | Q34319607 | ||
| The history and future of targeting cyclin-dependent kinases in cancer therapy | Q34460347 | ||
| The Medicinal Chemistry of Dengue Virus | Q34509221 | ||
| Targeting proteases: successes, failures and future prospects | Q34563752 | ||
| Novel benzoxazole inhibitor of dengue virus replication that targets the NS3 helicase | Q34583461 | ||
| The flavivirus protease as a target for drug discovery | Q34657530 | ||
| Viral protease inhibitors | Q34892265 | ||
| Pharmacokinetics of single-dose daptomycin in patients with suspected or confirmed neurological infections | Q35065838 | ||
| Novel therapeutic strategy for neurodegeneration by blocking Aβ seeding mediated aggregation in models of Alzheimer's disease | Q35070249 | ||
| Distribution of azithromycin into brain tissue, cerebrospinal fluid, and aqueous humor of the eye. | Q35123496 | ||
| A9145, a new adenine-containing antifungal antibiotic: fermentation | Q35645889 | ||
| Benzothiazole and Pyrrolone Flavivirus Inhibitors Targeting the Viral Helicase | Q35647755 | ||
| Suramin Inhibits Chikungunya Virus Entry and Transmission | Q35711583 | ||
| Viral and cellular RNA helicases as antiviral targets | Q36267887 | ||
| Virion-associated phosphatidylethanolamine promotes TIM1-mediated infection by Ebola, dengue, and West Nile viruses | Q36332001 | ||
| The enzymatic termination of polydeoxynucleotides by 2',3'-dideoxyadenosine triphosphate | Q36448864 | ||
| Concise drug review: azacitidine and decitabine | Q36871721 | ||
| Fetal safety of macrolides | Q36969814 | ||
| BCX4430 - A broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease | Q37077376 | ||
| Molecular strategies to inhibit the replication of RNA viruses | Q37099776 | ||
| Suramin is a potent inhibitor of Chikungunya and Ebola virus cell entry | Q37224249 | ||
| Molecular mechanism of divalent-metal-induced activation of NS3 helicase and insights into Zika virus inhibitor design | Q37473075 | ||
| Nitazoxanide inhibits the replication of Japanese encephalitis virus in cultured cells and in a mouse model | Q37590577 | ||
| Crystal structure of full-length Zika virus NS5 protein reveals a conformation similar to Japanese encephalitis virus NS5. | Q37698482 | ||
| The conformational changes of Zika virus methyltransferase upon converting SAM to SAH. | Q37716454 | ||
| Daptomycin: a review of properties, clinical use, drug delivery and resistance | Q37987183 | ||
| Novel therapies for hepatitis C - one pill fits all? | Q38117549 | ||
| Regulation of flavivirus RNA synthesis and capping | Q38127643 | ||
| A peptide-based viral inactivator inhibits Zika virus infection in pregnant mice and fetuses | Q38157419 | ||
| High-Content Screening in hPSC-Neural Progenitors Identifies Drug Candidates that Inhibit Zika Virus Infection in Fetal-like Organoids and Adult Brain. | Q38157498 | ||
| The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication | Q28595139 | ||
| Screening Bioactives Reveals Nanchangmycin as a Broad Spectrum Antiviral Active against Zika Virus | Q28595153 | ||
| N-(2-(arylmethylimino)ethyl)-7-chloroquinolin-4-amine derivatives, synthesized by thermal and ultrasonic means, are endowed with anti-Zika virus activity | Q28595161 | ||
| Perturbation in the conserved methyltransferase-polymerase interface of flavivirus NS5 differentially affects polymerase initiation and elongation | Q28651848 | ||
| Novel antiviral activity and mechanism of bromocriptine as a Zika virus NS2B-NS3 protease inhibitor | Q28729749 | ||
| Identification of novel small molecule inhibitors against NS2B/NS3 serine protease from Zika virus | Q28733552 | ||
| Real-Time Assessment of Health-Care Requirements During the Zika Virus Epidemic in Martinique | Q28804115 | ||
| Structural features of Zika virus non-structural proteins 3 and -5 and its individual domains in solution as well as insights into NS3 inhibition | Q28804200 | ||
| The Antigenic Structure of Zika Virus and Its Relation to Other Flaviviruses: Implications for Infection and Immunoprophylaxis | Q28804225 | ||
| 25-Hydroxycholesterol Protects Host against Zika Virus Infection and Its Associated Microcephaly in a Mouse Model | Q28950498 | ||
| The structure of Zika virus NS5 reveals a conserved domain conformation | Q29198404 | ||
| Crystal structure of Zika virus NS5 RNA-dependent RNA polymerase | Q29364910 | ||
| Increased activity of unlinked Zika virus NS2B/NS3 protease compared to linked Zika virus protease | Q29365202 | ||
| Solution conformations of a linked construct of the Zika virus NS2B-NS3 protease | Q29365272 | ||
| The crystal structure of Zika virus NS5 reveals conserved drug targets | Q29365336 | ||
| Structure and function of the Zika virus full-length NS5 protein | Q29365369 | ||
| Structure-based discovery of clinically approved drugs as Zika virus NS2B-NS3 protease inhibitors that potently inhibit Zika virus infection in vitro and in vivo | Q38157779 | ||
| Flavivirus RNA methylation | Q38184248 | ||
| Activity of recombinant dengue 2 virus NS3 protease in the presence of a truncated NS2B co-factor, small peptide substrates, and inhibitors. | Q38296304 | ||
| Effect of Pritelivir Compared With Valacyclovir on Genital HSV-2 Shedding in Patients With Frequent Recurrences: A Randomized Clinical Trial | Q38383305 | ||
| Suramin inhibits chikungunya virus replication through multiple mechanisms | Q38859980 | ||
| Structural basis of Zika virus methyltransferase inhibition by sinefungin | Q38867867 | ||
| Microcephaly and Zika virus infection | Q39404041 | ||
| Zika virus detection in cerebrospinal fluid from two patients with encephalopathy, Martinique, February 2016. | Q39412614 | ||
| Zika Virus: a re-emerging pathogen with rapidly evolving public health implications | Q39753281 | ||
| Development of antiretroviral therapy for the acquired immunodeficiency syndrome and related disorders. A progress report | Q39755409 | ||
| Substrate selectivity of Dengue and Zika virus NS5 polymerase towards 2'-modified nucleotide analogues | Q40051088 | ||
| Structure of the NS5 methyltransferase from Zika virus and implications in inhibitor design | Q40052562 | ||
| Sexual transmission of Zika virus in an entirely asymptomatic couple returning from a Zika epidemic area, France, April 2016. | Q40057882 | ||
| Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus. | Q40484115 | ||
| Fascioliasis: diagnosis, epidemiology and treatment | Q40534360 | ||
| Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft | Q40763120 | ||
| Response of human-immunodeficiency-virus-associated neurological disease to 3'-azido-3'-deoxythymidine | Q41343118 | ||
| Helicase-primase inhibitor pritelivir for HSV-2 infection | Q42243140 | ||
| Severe psychiatric side effects observed during prophylaxis and treatment with mefloquine | Q42282207 | ||
| Substrate profiling of Zika virus NS2B-NS3 protease. | Q42998302 | ||
| Clinical trial: the efficacy and safety of oral PF-03491390, a pancaspase inhibitor - a randomized placebo-controlled study in patients with chronic hepatitis C. | Q43159165 | ||
| Maternal and transplacental pharmacokinetics of azithromycin | Q43731956 | ||
| A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma | Q43887370 | ||
| Successful treatment of acute fascioliasis with bithionol | Q43922035 | ||
| Pharmacokinetics of ivermectin after maternal or fetal intravenous administration in sheep | Q46254066 | ||
| Stereoselective passage of mefloquine through the blood-brain barrier in the rat. | Q48584373 | ||
| FDA approves 3TC and saquinavir. Food and Drug Administration. | Q54155250 | ||
| Nucleosides. V. The Monomesylates of 1-(2'-Deoxy-β-D-lyxofuranosyl)thymine1,2 | Q56156635 | ||
| Pregnancy Outcome Among Twins Conceived After Subfertility Treatment Compared With Natural Twins: A Population-Based Study | Q57744941 | ||
| Niclosamide treatment of cestodiasis. Clinicial trials in the United States | Q71449841 | ||
| Fatal Guillain-Barré syndrome | Q74455876 | ||
| CONTACT PHOTODERMATITIS FROM BITHIONOL. II. CROSS-SENSITIVITIES TO HEXACHLOROPHENE AND SALICYLANILIDES | Q76847439 | ||
| Hepatitis C: staying the course | Q80162597 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Zika virus | Q202864 |
| Zika virus infection | Q27043680 | ||
| P1104 | number of pages | 22 | |
| P5008 | on focus list of Wikimedia project | WikiProject Zika Corpus | Q54439832 |
| P304 | page(s) | 1027-1048 | |
| P577 | publication date | 2017-09-26 | |
| P1433 | published in | Neurotherapeutics | Q15716631 |
| P1476 | title | Therapeutic Approaches for Zika Virus Infection of the Nervous System | |
| P478 | volume | 14 |
| Q58122069 | Complementary Mechanisms Potentially Involved in the Pathology of Zika Virus |
| Q90419101 | Importance of Zika Virus NS5 Protein for Viral Replication |
| Q58664017 | Therapeutic treatment of Zika virus infection using a brain-penetrating antiviral peptide |
| Q89709681 | Zika virus-spread, epidemiology, genome, transmission cycle, clinical manifestation, associated challenges, vaccine and antiviral drug development |
Search more.